Analysts await FibroGen, Inc (NASDAQ:FGEN) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.69 EPS, up 13.04% or $0.09 from last year’s $-0.78 per share.

At the moment 8 analysts are watching FibroGen, Inc (NASDAQ:FGEN), 4 rate it “Buy”, 3 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 6 analysts have a mean sales target of 76.86 million. For the quarter ending Sep-16, 6 analysts have a mean sales target of 23.10 million whilst for the year ending Dec-16, 7 analysts have a mean target of 165.95 million.

In terms of earnings per share, 7 analysts have a 0.33 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 7 analysts have a -0.53 EPS mean target and for the quarter ending Sep-16 there are 8 estimates of -1.14 EPS.

The biggest institutional shareholders in FibroGen, Inc include Vanguard Group Inc which owns 4 million shares in the company valued at $109.29 million. Adage Capital Partners Gp LLC is the second biggest holder with 2 million shares currently valued at 62.77 million whilst Visium Asset Management LP has 2 million shares valued at 61.91 million.

Total shares held by institutions as of the most recent company filings are 30,859,007 with a reported 2,872,211 bought and 2,499,419 sold. These holdings make up 49.9% of the company’s outstanding shares.

Currently insiders hold 5,188,138 shares in the business which makes up 8.36% of shares. The biggest holder currently is Mr. Thomas B. Neff who owns 3,538,853 shares (5.70% of those outstanding), whilst Mr. Rory B. Riggs holds 480,200 (0.77% of shares outstanding) and Dr. K. Peony Yu, M.D. holds 218,729 (0.35% of shares outstanding).

The stock decreased 2.65% or $0.43 during the last trading session.